We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .
Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial.
BACKGROUND In chronic kidney disease ( CKD ) , loop diuretics correct volume-dependent hypertension , but their effect on left ventricular mass index ( LVMI ) is unknown . METHODS Forty hypertensive CKD patients ( estimated creatinine clearance 60 - 15 mL/min/1.73 m² ) , treated with renin-angiotensin system ( RAS ) inhibitors , were r and omized to  receive furosemide or non-diuretic antihypertensive treatment ( control group )  . Office blood pressure ( BP ) < 130/80 mmHg was pursued in both groups . Primary end point was the reduction of LVMI after 52 weeks . Secondary aims were to verify safety related to furosemide treatment and its effects on ambulatory and clinic BP and body fluid volumes . RESULTS Office BP similarly declined in the furosemide group ( from 161 ± 14/80 ± 10 to 139 ± 14/74 ± 8 mmHg ) and in controls ( from 159 ± 16/81 ± 10 to 137 ± 16/75 ± 10 mmHg ) . We detected a greater reduction ( P = 0.013 ) of LVMI in patients receiving furosemide ( -7.9 , IQR from -15.8 to -1.4 g/h(2.7 ) ) than in controls ( 0.0 , IQR from -6.2 to + 9.5 g/h(2.7 ) , P = 0.013 ) . Bio-impedance analysis -derived extracellular water ( ECW ) significantly decreased in furosemide-treated patients ( from 18.7 ± 3.9 to 17.7 ± 3.3 L ) while remained unchanged in the control group ( from 19.5 ± 2.2 to 19.6 ± 1.9 L ) . Absolute change of LVMI correlated with changes of ECW in furosemide-treated patients ( r = 0.458 , P = 0.042 ) but not in controls . In the furosemide group , no patient experienced side effects requiring drug withdrawal . CONCLUSIONS In hypertensive CKD patients treated with RAS inhibitors  , add-on furosemide efficaciously reduces LVMI independently from BP changes . The effect is possibly mediated by better control of volume expansion
We found no clinical ly meaningful blood pressure-lowering differences between different drugs within the loop diuretic class .
BACKGROUND Antihypertensive drugs from the thiazide diuretic drug class have been shown to reduce mortality and cardiovascular morbidity .
Loop diuretics are indicated and used to treat hypertension , but a systematic review of their blood pressure-lowering efficacy or effectiveness in terms of reducing cardiovascular mortality or morbidity from r and omized controlled trial ( RCT ) evidence has not been conducted .
OBJECTIVES To determine the dose-related decrease in systolic or diastolic blood pressure , or both , as well as adverse events leading to participant withdrawal and adverse biochemical effects ( serum potassium , uric acid , creatinine , glucose and lipids profile ) due to loop diuretics versus placebo control in the treatment of people with primary hypertension .